Status:
TERMINATED
A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine
Lead Sponsor:
Pfizer
Conditions:
Breast Neoplasms
Eligibility:
FEMALE
18+ years
Phase:
PHASE3
Brief Summary
To compare efficacy and safety of Sunitinib and Capecitabine in subjects with advanced breast cancer who failed both a taxane and an anthracycline chemotherapy regimen or failed with a taxane and for ...
Detailed Description
Patient enrollment in this trial was discontinued based on statistical assessment for futility. An independent Data Monitoring Committee found that even if the trial had been allowed to continue, trea...
Eligibility Criteria
Inclusion
- breast adenocarcinoma
- prior treatment with an anthracycline and a taxane either concurrently or sequentially in the neoadjuvant, adjuvant and or/ advanced disease treatment settings. No more than 1 chemotherapy regimen in the advanced setting
Exclusion
- Prior treatment with regimens of chemotherapy in the advanced/metastatic disease setting beyond those containing anthracyclines and taxanes or multiple anthracyclines/ taxanes treatments.
- Any prior regimen with capecitabine
Key Trial Info
Start Date :
November 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2011
Estimated Enrollment :
482 Patients enrolled
Trial Details
Trial ID
NCT00373113
Start Date
November 1 2006
End Date
June 1 2011
Last Update
June 25 2012
Active Locations (123)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Córdoba, Córdoba Province, Argentina, X5000AAI
2
Pfizer Investigational Site
Bahía Blanca, Prov. de Buenos Aires, Argentina, B8001HXM
3
Pfizer Investigational Site
Viedma, Río Negro Province, Argentina, 8500
4
Pfizer Investigational Site
Rosario, Santa Fe Province, Argentina, (2000)